Amendments to the Claims

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

Claims 1-111 cancelled.

Claim 112 (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is $-S(O)_2-$; and

Z is $-NR^1R^2$; wherein R^2 is optionally substituted heteroaryl and R^1 is hydrogen or lower alkyl.

Claim 113 (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of 5-Pentafluorophenylsulfonamidoindazole, 5-Pentafluorophenylsulfonamidoindole; 4-Methyl-6-methoxy-2-pentafluorophenylsulfonamidopyrimidine; 4,6-Dimethoxy-2-pentafluorophenylsulfonamidopyrimidine; 2-Pentafluorophenylsulfonamidothiophene; 3-Pentafluorophenylsulfonamidothiophene; 3-Pentafluorophenylsulfonamidopyridine; 4-Pentafluorophenylsulfonamidopyridine; 2-Chloro-5-pentafluorophenylsulfonamidopyridine; 6-Pentafluorophenylsulfonamidoquinoline; 5-Pentafluorophenylsulfonamidobenzo[a]thiophene; 5-Pentafluorophenylsulfonamidobenzo[a]furan; 2-Methoxy-5-Pentafluorophenylsulfonamidopyridine; and 2-Anilino-3--

pentafluorophenylsulfonamidopyridine.

Claim 114 (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is $-SO_2-$; and

Z is $-NR^1R^2$; wherein R^2 is an optionally substituted heteroaryl and R^1 is an optionally substituted (C2-ClO)alkyl or optionally substituted (C2-C6)heteroalkyl, and

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms.

Claim 115 (New) A method of treating a disease selected from the group consisting of atherosclerosis, pancreatitis, hypercholesterolemia, and hyperlipoproteinemia which method

comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition containing a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

wherein:

Y is -S(O)- or -$S(O)_2$-;

Z is -NR^1R^2; where R^2 is optionally substituted heteroaryl and R^1 is selected from

hydrogen,

substituted or unsubstituted (Cl-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

substituted or unsubstituted heteroaryl,

substituted or unsubstituted heteroaryloxy,

substituted or unsubstituted heteroaryl-(C1-C4)alkyl,

substituted or unsubstituted heteroaryl-(Cl-C4)alkoxy,

substituted or unsubstituted heteroaryl-(C1-C4)heteroalkyl,

substituted or unsubstituted heteroaryl-(C3-C6)alkenyl,

substituted or unsubstituted heteroaryloxy-(CI-C4)alkyl, and

substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen;

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-

phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen.

Claim 116 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition containing a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a hypolipemic agent or a hypocholesterolemic agent that is not represented by formula I:



I

wherein in formula I:

Y is -S(O)- or -$S(O)_2$-;

Z is -NR^1R^2; where R^2 is optionally substituted heteroaryl and R^1 is selected from

hydrogen,

substituted or unsubstituted (Cl-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

substituted or unsubstituted heteroaryl,

substituted or unsubstituted heteroaryloxy,

substituted or unsubstituted heteroaryl-(C1-C4)alkyl,

substituted or unsubstituted heteroaryl-(Cl-C4)alkoxy,

substituted or unsubstituted heteroaryl-(C1-C4)heteroalkyl,

substituted or unsubstituted heteroaryl-(C3-C6)alkenyl,

substituted or unsubstituted heteroaryloxy-(CI-C4)alkyl, and

substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the

ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen;

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen.

Claim 117 (New) A pharmaceutical composition according to claim 112 wherein R^2 is an optionally substituted pyridyl.

Claim 118 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition of claim 112.

Claim 119 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition of claim 113.

Claim 120 (New) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is –S(O)- or $-SO_2$-; and

Z is $-NR^1R^2$; wherein R^2 is an optionally substituted heteroaryl group having only one or two heteroatoms in the heteroaryl ring system thereof, and R^1 is an optionally substituted (C2-C10)alkyl or optionally substituted (C2-C6)heteroalkyl, and

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms,

wherein said compound has pharmacological activity; and

with the proviso that heteroaryl is other than 4-pyrimidyl.

Claim 121 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition containing a compound of formula I, or a pharmaceutically acceptable salt thereof,



I

wherein:

Y is $-S(O)_2-$;

Z is $-NR^1R^2$; where R^2 is optionally substituted heteroaryl and R^1 is an optionally susbstituted (C2-C10)alkyl or optionally substituted (C2-C6)heteroalkyl and

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms.

Claim 122 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition containing a compound of formula I, or a pharmaceutically acceptable salt thereof,



I

wherein:

Y is -S(O)- or -$S(O)_2$-;

Z is -NR^1R^2; where R^2 is a monocyclic heteroaryl group and R^1 is selected from

hydrogen,

substituted or unsubstituted (Cl-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

substituted or unsubstituted heteroaryl,

substituted or unsubstituted heteroaryloxy,

substituted or unsubstituted heteroaryl-(C1-C4)alkyl,

substituted or unsubstituted heteroaryl-(Cl-C4)alkoxy,

substituted or unsubstituted heteroaryl-(C1-C4)heteroalkyl,

substituted or unsubstituted heteroaryl-(C3-C6)alkenyl,

substituted or unsubstituted heteroaryloxy-(CI-C4)alkyl, and

substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen;

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen.

Claim 123 (New) A method of treating a disease state, characterized by abnormally high low density lipoprotein particles or cholesterol levels in the blood, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition containing a compound of formula I, or a pharmaceutically acceptable salt thereof,



I

wherein:

Y is -S(O)- or -$S(O)_2$-;

Z is -NR^1R^2; where R^2 is an optionally substituted heteroaryl having only one heteroatom in the heteroaryl ring system and R^1 is selected from

hydrogen,

substituted or unsubstituted (Cl-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

substituted or unsubstituted heteroaryl,

substituted or unsubstituted heteroaryloxy,

substituted or unsubstituted heteroaryl-(C1-C4)alkyl,

substituted or unsubstituted heteroaryl-(Cl-C4)alkoxy,

substituted or unsubstituted heteroaryl-(C1-C4)heteroalkyl,

substituted or unsubstituted heteroaryl-(C3-C6)alkenyl,

substituted or unsubstituted heteroaryloxy-(CI-C4)alkyl, and

substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-

pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen;

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen.

Claim 124 (New) A method of reducing the level of low density lipoprotein particles levels or cholesterol in the blood of a mammalian subject in need thereof, which method comprises administering to said subject a therapeutically effective amount of a composition containing a compound of formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is $-S(O)-$ or $-S(O)_2-$; and

Z is $-NR^1R^2$; where R^2 is an optionally substituted heteroaryl group having only one or only two heteroatoms in the heteroaryl ring system thereof, and R^1 is selected from

hydrogen,

substituted or unsubstituted (C2-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^1 is hydrogen or methyl, then R^2 is a substituted heteroaryl group;

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen and;

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen;

wherein said compound has pharmacological activity; and

with the proviso that the heteroaryl is other than 4-pyrimidyl,

whereby said level of low density lipoprotein particles or cholesterol is reduced.

Claim 125 (New) A method of claim 124, wherein the subject is human.

Claim 126 (New) A compound having the formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is $-S(O)-$ or $-S(O)_2-$; and

Z is $-NR^1R^2$; where R^2 is an optionally substituted heteroaryl selected from the group consisting of 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-

thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl, and R^1 is selected from

hydrogen,

substituted or unsubstituted (C2-C10)alkyl,

substituted or unsubstituted (C1-C10)alkoxy,

substituted or unsubstituted (C3-C6)alkenyl,

substituted or unsubstituted (C2-C6)heteroalkyl,

substituted or unsubstituted (C3-C6)heteroalkenyl,

substituted or unsubstituted (C3-C6)alkynyl,

substituted or unsubstituted (C3-C8)cycloalkyl,

substituted or unsubstituted (C5-C7)cycloalkenyl,

substituted or unsubstituted (C5-C7)cycloalkadienyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aryloxy,

substituted or unsubstituted aryl-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(C5-C7)cycloalkenyl,

substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl,

substituted or unsubstituted aryl-(Cl-C4)alkyl,

substituted or unsubstituted aryl-(C1-C4)alkoxy,

substituted or unsubstituted aryl-(Cl-C4)heteroalkyl,

substituted or unsubstituted aryl-(C3-C6)alkenyl,

substituted or unsubstituted aryloxy-(C1-C4)alkyl,

substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl,

wherein R^1 and R^2 of $-NR^1R^2$ may be connected by a linking group E to give a substituent of the formula



wherein E represents a bond, (C1-C4)alkylene, or (C1-C4)heteroalkylene and the ring formed by R^1, E, R^2 and the nitrogen contains no more than 8 atoms;

provided that:

in the case that Y is $-S(O_2)-$, and R^1 is hydrogen or methyl, then R^2 is a substituted heteroaryl group;

in the case that Y is $-S(O_2)-$, and R^2 is a ring system chosen from 5-quinolyl, or 4-pyridyl, then either R^1 is not hydrogen or R^2 is substituted by at least one substituent that is not hydrogen; and

in the case that Y is $-S(O_2)-$ and R^2 is 2-methylbenzothiazol-5-yl, 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, 5-carbomethoxypyrazin-2-yl, 4-carboethoxy-l-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-l-,3-,4-thiadiazol-5-yl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-l,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin 2-yl, or 3-cyanopyrazol-4-yl, then R^1 is a group other than hydrogen

wherein said compound has pharmacological activity.

Claim 127 (New) The compound of claim 126, wherein R^1 is hydrogen or lower alkyl, Y is $-S(O_2)-$, and there is no linking group between R^1 and R^2.

Claim 128 (New) The compound of claim 126, wherein R^1 is other than unsubstituted (C2-C10)alkyl.